RRP22: a novel neural tumor suppressor for astrocytoma.
Astrocytomas are the most common neoplasm of the central nervous system. Although progress has been made, the survival rate of astrocytoma is still poor. Therefore, improving the prognosis of patients with astrocytomas relies on effective therapies that are directed against unique molecular aberrations. Previous studies have revealed that a novel member of the Ras superfamily, RRP22, which is located on chromosome 22 on the 12q site, is exclusively expressed in the central nervous system. RRP22 can be modified by farnesyl and down-regulated in a variety of neural tumor cell lines. In this study, we analyzed the mRNA level of RRP22 in normal brain tissues and astrocytomas using quantitative RT-PCR. Our results showed that the mRNA level in astrocytomas was significantly down-regulated compared to levels in normal tissues. As the pathological grade (World Health Organization (WHO) classification 2007) increased, the expression of RRP22 decreased. However, according to our research, there was no significant difference between malignant astrocytomas with pathological grades of III or IV. To investigate the possible effects of RRP22 on the biological behavior of glioma cells, we transfected RRP22 into a malignant cell line of astrocytomas, U251. We found that RRP22 inhibited growth, decreased invasiveness, and induced cell death. Thus, RRP22 is a special neural tumor suppressor for human astrocytomas, although further studies are needed to define the detailed mechanisms.
Department of Neurosurgery, Xiangya Hospital of Central South University, 410078 Changsha, Hunan, People's Republic of China.
Ruokun
R
Chen
Liang
L
Yang
Jiasheng
J
Fang
Lei
L
Huo
Mingyu
M
Zhang
Fenghua
F
Chen
Jinfang
J
Liu
Jun
J
Wu
Yanjin
Y
Wang
D001254:Astrocytoma / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D015153:Blotting, Western; D001932:Brain Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D002465:Cell Movement / Q000235:genetics; D049109:Cell Proliferation; D005434:Flow Cytometry; D006801:Humans; D046529:Microscopy, Electron, Transmission; D060787:Neoplasm Grading; D012333:RNA, Messenger / Q000032:analysis; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014162:Transfection; D025521:Tumor Suppressor Proteins / Q000235:genetics / Q000378:metabolism*; D018631:ras Proteins / Q000235:genetics / Q000378:metabolism*
D012333:RNA, Messenger; D025521:Tumor Suppressor Proteins; C104142:RASL10A protein, human; D018631:ras Proteins
Neuro Oncol. 2008 Dec;10(6):1004-9
18725460
Cancer Lett. 2004 Oct 28;214(2):205-13
15363547
Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14559-63
8962091
Oncogene. 2002 Nov 14;21(52):8011-9
12439751
Genomics. 1996 Dec 15;38(3):247-54
8975699
Cell Res. 2010 May;20(5):553-62
20386572
J Clin Oncol. 2006 Aug 1;24(22):3651-6
16877733
Science. 2004 Jul 30;305(5684):626-9
15286356
Acta Neuropathol. 2004 Dec;108(6):467-70
15517309
J Biol Chem. 1996 Oct 11;271(41):25639-45
8810340
Dev Cell. 2004 Apr;6(4):463-77
15068787
Brain Pathol. 2007 Jul;17(3):304-7
17598822
Eur J Cancer. 2009 May;45(7):1294-1303
19179066
J Clin Oncol. 2006 Apr 1;24(10):1627-32
16575014
Oncogene. 1997 Mar 6;14(9):1075-81
9070656
Cancer Res. 2005 Apr 15;65(8):3117-25
15833841
Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):214-9
9874798
Oncogene. 1997 Dec 4;15(23):2755-65
9419966
Cell Death Differ. 2010 May;17(5):821-32
19911005
Oncogene. 2008 Oct 27;27(50):6452-61
18955972